# ORIENT-31 (NCT03802240)

> Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure

No report yet. It can be ordered.

- Drugs tested: sintilimab plus IBI305; sintilimab
- Indication: EGFR-mutated non-squamous NSCLC after EGFR-TKI treatment failure

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03802240
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
- Conditions: Non-Squamous Non-Small Cell Lung Cancer
- Interventions: Sintilimab; IBI305; Pemetrexed; Cisplatin; Placebo1; Placebo2
- Enrollment: 492
- Primary outcome: PFS (Progression Free Survival)

## Indexed commentary on ORIENT-31 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 26 posts on X
- 13 podcast episodes
- 7 YouTube videos

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=orient-31-nct03802240

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03802240", "email": "<work email>"}; the inbox owner confirms by the emailed link.